debt_leverage_profile
Pre-revenue biotech; minimal debt, primarily equity-funded via venture capital; near-zero leverage ratio as of 2023-2024.
Inferred
Agent_Inference
interest_rate_sensitivity
Low direct sensitivity; no significant floating-rate debt. Higher rates increase opportunity cost of cash runway and compress biotech valuations.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) Oligopolistic RNA synthesis reagent suppliers (Thermo Fisher, Sigma-Aldrich); 2) AAV/LNP manufacturing CDMOs concentrated in US/Europe.
Inferred
Agent_Inference
international_expansion_readiness
Preclinical-stage US-focused company; no international revenue markets; sovereign currency devaluation exposure is effectively zero.
Inferred
Agent_Inference
geographic_footprint
Operations concentrated in Cambridge, MA; no meaningful international commercial footprint; USD-denominated cost and funding structure.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on specialized ADAR-editing oligonucleotide synthesis vendors and CDMO partners; limited substitutability for GMP RNA manufacturing.
Inferred
Agent_Inference
business_model_type_primary
Cloud disruption risk is low-moderate; research informatics and data pipelines could be disrupted, but core wet-lab IP is not cloud-dependent.
Inferred
Agent_Inference
business_model_type_secondary
Biotech R&D platform; would require 3-6 months to migrate computational workloads but physical lab operations would continue uninterrupted.
Inferred
Agent_Inference
switching_cost_profile
Moderate API/platform coupling risk via bioinformatics tools; proprietary ADAR-editing algorithms represent internal IP with limited third-party API dependency.
Inferred
Agent_Inference
howey_test_risk_index
Not applicable; Korro Bio is a private biotech generating no product revenue; Howey Test not relevant to its licensing/milestone revenue model.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Minimal; handles genomic research data internally; limited patient data at preclinical stage; GDPR/CCPA exposure low but will rise with clinical trials.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche RNA editing platform in emerging competitive landscape; no dominant market position warranting regulatory scrutiny.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Currently 100% transactional/milestone-based; no recurring subscription revenue. Revenue derived from pharma partnerships and research collaborations.
Inferred
Agent_Inference
monetization_vector
Pharma partnership milestones, upfront licensing fees, and potential royalties on future commercialized RNA-editing therapeutics.
Inferred
Agent_Inference
pricing_architecture
Milestone-based pricing negotiated with large pharma partners; pricing power constrained by few large counterparties but protected by proprietary platform.
Inferred
Agent_Inference
pricing_power_rating
Moderate; differentiated ADAR-editing platform provides negotiating leverage, but dependence on 1-2 pharma partners limits sustained pricing power.
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margin 70-85% on licensing/milestone revenue; R&D costs are largely below gross margin line in partnership deal structures.
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider problem; proprietary platform with patent protection. Risk is partner non-renewal after milestone payments, not free-riding.
Inferred
Agent_Inference
headcount_cost_structure
Headcount-linear at current stage; scaling RNA-editing programs requires proportional scientific staff. Sublinear only achievable post-platform maturation.
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost of growth; each new therapeutic program requires dedicated R&D headcount, lab resources, and CDMO manufacturing capacity.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Korro Bio does not operate a franchise model.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale (multiple approved drugs), partnership economics improve but CAC remains high; BD and regulatory costs scale with program count.
Inferred
Agent_Inference
network_effect_present
No traditional network effects; platform value grows with proprietary ADAR-editing data and IP accumulation, not user-scale dynamics.
Inferred
Agent_Inference
asset_efficiency_ratio
-102.7% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; large pharma R&D budgets are relatively recession-resistant, but venture funding and partnership appetite can contract.
Inferred
Agent_Inference
customer_segment_primary
Large pharmaceutical and biopharmaceutical companies seeking RNA-editing platform access for genetic disease programs.
Inferred
Agent_Inference
customer_segment_secondary
Academic/research institutions and rare disease foundations as secondary collaborators for early-stage discovery and grant-funded research.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
8.1% CapEx / Revenue (Moderate-CapEx)
High
SEC-XBRL
sec_cik
0001703647
High
SEC-EDGAR
ticker
KRRO
High
SEC-EDGAR